Comparative Pharmacology
Head-to-head clinical analysis: DYCILL versus OMNIPEN N.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYCILL versus OMNIPEN N.
DYCILL vs OMNIPEN-N
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin G benzathine is a slow-release parenteral formulation of penicillin G that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
Omnipen-N (ampicillin sodium) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby interfering with transpeptidation and resulting in cell lysis.
250 mg orally every 6 hours or 500 mg orally every 12 hours.
250-500 mg orally every 6 hours for adults; for severe infections, up to 1 g every 6 hours.
None Documented
None Documented
0.5-1 hour; prolonged in renal impairment (up to 20 hours in severe cases).
30-60 minutes (normal renal function); prolonged to 7-10 hours in severe renal impairment (CrCl <10 mL/min).
Renal: approx. 60-80% unchanged by glomerular filtration and tubular secretion. Biliary/fecal: minor (less than 10%).
Primarily renal (80-90% unchanged via tubular secretion); minor biliary/fecal (<10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic